Sientra Announces Departure of CFO and Appointment of Interim CFO
March 11 2021 - 04:01PM
Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a
medical aesthetics company uniquely focused on plastic surgeons,
today announced that Paul Little is stepping down from his position
as Chief Financial Officer, Senior Vice President and Treasurer, to
pursue other opportunities effective March 12, 2021. Valerie
Miller, current Vice President, Corporate Controller, will serve as
interim Chief Financial Officer effective upon Mr. Little’s
resignation as the Company completes its search for a permanent
replacement.
“We thank Paul for his diligent work and greatly
appreciate all his contributions to our team through his tenure at
Sientra,” said Ron Menezes, President and Chief Executive Officer
of Sientra. “He was integral in positioning our company for durable
future growth by strengthening our balance sheet and driving
efficiencies to accelerate our path to revenue growth and we wish
him well in his future endeavors.”
“It has been a privilege to work alongside the
entire Sientra team and to have been a part of the company’s growth
story,” said Mr. Little. “While stepping down was a difficult
decision, and one based solely on personal reasons, I am confident
that Sientra will remain on a solid path forward under Ron’s
leadership.”
Mr. Menezes added, "Given her strong knowledge
of our business and financial reporting standards I have great
confidence in Ms. Miller’s ability to lead the finance team on an
interim basis as we recruit a new Chief Financial Officer. We
expect that the transition will have no material impact on our
operations, and we remain confident in our near-term growth
prospects as we remain well capitalized with a highly efficient
team."
Ms. Miller joined Sientra in September 2017 as
Vice President, Corporate Controller and has since been responsible
for the accounting and finance functions of the Company. Prior to
joining Sientra, Ms. Miller served as Corporate Controller at The
Trade Desk, Inc. and as Senior Director of Finance & Accounting
at LinkedIn. Previously, she served as a Vice President on the
finance team of Mentor Worldwide, a subsidiary of Johnson &
Johnson. Ms. Miller holds a Bachelor’s in Economics from the
University of California, Santa Barbara.
Mr. Little’s departure is not related to any
disagreement with the company’s accounting principles or practices
or financial statement disclosures.
About Sientra
Headquartered in Santa Barbara, California,
Sientra is a medical aesthetics company uniquely focused on plastic
surgeons. The Company offers a suite of products designed to make a
difference in patients' lives by enhancing their body image,
growing their self-esteem, and restoring their confidence. Sientra
has developed a broad portfolio of products with technologically
differentiated characteristics, supported by independent laboratory
testing and strong clinical trial outcomes. The Company’s Breast
Products Segment includes its Sientra round and shaped breast
implants, the first fifth generation breast implants approved by
the FDA for sale in the United States, its ground-breaking Allox2®
breast tissue expander with patented dual-port and integral drain
technology, and BIOCORNEUM® the #1 performing, preferred and
recommended scar gel of plastic surgeons(*). The Company’s miraDry
Segment, comprised of its miraDry® system, is approved for sale in
over 56 international markets and is the only non-surgical,
FDA-cleared device indicated for the permanent reduction of
underarm sweat and hair and may also reduce odor.
Sientra uses its investor relations website
to publish important information about the Company, including
information that may be deemed material to investors. Financial and
other information about Sientra is routinely posted and
is accessible on the Company’s investor relations website
at www.sientra.com.
(*) Data on file
Forward-Looking Statements
This press release contains “forward-looking
statements” within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. These statements include statements regarding
the CFO transition and employment matters related thereto and the
Company’s growth prospects. Such statements are based on current
assumptions that involve risks and uncertainties that could cause
actual outcomes and results to differ materially. These risks and
uncertainties, many of which are beyond our control, include risks
described in the section entitled “Risk Factors” and elsewhere in
our filings made with the Securities and Exchange Commission. These
forward-looking statements speak only as of the date hereof and
should not be unduly relied upon. Sientra disclaims any obligation
to update these forward-looking statements.
ContactInvestor Relations805-679-8885
Sientra (NASDAQ:SIEN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Sientra (NASDAQ:SIEN)
Historical Stock Chart
From Mar 2023 to Mar 2024